A Phase 2, Blinded, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-4875 in Subjects with Moderately to Severely Active Ulcerative Colitis
Latest Information Update: 26 Aug 2022
At a glance
- Drugs Tilpisertib (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms Falcon
- Sponsors Gilead Sciences
Most Recent Events
- 29 Jul 2022 Status changed from completed to discontinued.
- 05 Jan 2022 Status changed from active, no longer recruiting to completed.
- 29 Jan 2021 This trial has been completed in Austria, according to European Clinical Trials Database record.